These data may explain why women with ER-negative and PgR-positive disease in the EBCTCG meta-analysis showed a trend towards initial benefit from adjuvant tamoxifen, an observation which was lost with longer follow-up.
← all excerpts
Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.
1
—
—